Aspirin – Medxy AI

Ticagrelor Plus Aspirin Versus Aspirin Alone After Coronary Artery Bypass Grafting in Acute Coronary Syndrome: A Contemporary Evidence Synthesis

By MedXY 12/18/2025

This review synthesizes current evidence on the efficacy and safety of ticagrelor combined with aspirin compared to aspirin alone following CABG for acute coronary syndrome, highlighting the 2025 TACSI trial and its implications for clinical practice.

Cardiology Internal Medicine news

Aspirin in the Healthy Elderly: ASPREE’s Clear Message — No Benefit, Higher Bleeding, and Unexpected Cancer Signal

By MedXY 11/28/2025

ASPREE randomized ~19,000 older adults to low‑dose aspirin or placebo. Over ~4.7 years, aspirin did not improve disability‑free survival or reduce cardiovascular events, increased major bleeding, and showed a surprising rise in cancer‑related death; extended follow‑up confirmed no long‑term MACE benefit.

Cardiology news

Summary of ARIES-HM3 Clinical Trial Publications on Aspirin Use and Hemocompatibility in LVAD Patients

By MedXY 11/28/2025

Comprehensive review of ARIES-HM3 trial findings showing aspirin avoidance with vitamin K antagonists in HeartMate 3 LVAD patients reduces bleeding without increasing thrombotic events, supported by analyses across subgroups and anticoagulation quality.

Cardiology news

Aspirin Use in Chronic Coronary Syndrome Patients on Oral Anticoagulation: Balancing Risks and Benefits

By MedXY 10/31/2025

A randomized trial revealed that adding aspirin to oral anticoagulation in chronic coronary syndrome patients increases adverse cardiovascular events, mortality, and major bleeding, challenging conventional dual therapy approaches.

Cardiology Neurology news

Apixaban Versus Aspirin for Recurrent Stroke Prevention in Patients with Left Ventricular Dysfunction: Insights from a Secondary Analysis of the ARCADIA Trial

By MedXY 10/29/2025

A secondary analysis of the ARCADIA trial reveals that apixaban significantly reduces recurrent ischemic stroke risk compared to aspirin in patients with left ventricular systolic dysfunction post-cryptogenic stroke.

Ophthalmology Specialties

Intravenous Alteplase Versus Oral Aspirin in Acute Central Retinal Artery Occlusion: Insights from the THEIA Phase 3 Trial and Contextual Evidence

By MedXY 10/22/2025

THEIA trial evaluated intravenous alteplase against oral aspirin in acute CRAO within 4.5 hours; no significant visual improvement difference was found, emphasizing the need for further research and meta-analyses to clarify thrombolysis benefits.

Cardiology Hematology-Oncology news

Clonal Hematopoiesis in Older Adults: Implications for Cardiovascular Risk, Bleeding, and Aspirin Use

By MedXY 10/15/2025

This study reveals that clonal hematopoiesis of indeterminate potential (CHIP) in adults aged 70+ does not increase cardiovascular risk but is associated with heightened bleeding risk. Aspirin showed no additional benefits or harms for those with CHIP in primary prevention of cardiovascular events.

Cardiology news

Clopidogrel versus Aspirin for Secondary Prevention in Coronary Artery Disease: A Comprehensive Meta-Analysis

By MedXY 10/11/2025

This meta-analysis of nearly 29,000 CAD patients shows clopidogrel monotherapy reduces major cardiovascular events more than aspirin without increasing major bleeding risk, supporting clopidogrel as preferred secondary prevention.

Internal Medicine Neurology news

Aspirin Use in Older Adults: Insights from the ASPREE-XT Study on Healthy Lifespan

By MedXY 10/07/2025

Extended follow-up from the ASPREE-XT study shows low-dose aspirin does not improve healthy lifespan—defined as survival free of dementia, persistent disability, or death—in healthy older adults, and its risks include increased major hemorrhagic events.

Cardiology Clinical Updates news

Aspirin vs. Clopidogrel Monotherapy Following PCI: Insights from the STOPDAPT-3 1-Year Follow-up

By MedXY 09/22/2025

The STOPDAPT-3 trial compared aspirin and clopidogrel monotherapy after short dual antiplatelet therapy in PCI patients, showing similar cardiovascular and bleeding outcomes at 1 year.

Cardiology

Aspirin Versus Clopidogrel After Acute Coronary Syndrome: Insights from STOPDAPT-3 in High-Bleeding Risk and STEMI Patients

By MedXY 09/22/2025

STOPDAPT-3 trial shows aspirin and clopidogrel yield comparable cardiovascular and bleeding outcomes 1 month to 1 year post-PCI in ACS patients, regardless of bleeding risk or STEMI status.

Clinical Updates news OB/GYN & Women's Health Specialties

Aspirin for Delaying Preterm Birth in High-Risk Preterm Pre-eclampsia Pregnancies: Insights from a Multicenter Randomized Trial in Asia

By MedXY 09/19/2025

Early low-dose aspirin reduces early preterm birth risk and delays timing of delivery in women at high risk for preterm pre-eclampsia, with significant benefits in iatrogenic preterm births and small-for-gestational-age pregnancies.

Clinical Updates Oncology

Adjuvant Aspirin in PIK3CA-Mutated Colon Cancer: Insights from the SAKK 41/13 Randomized Trial

By MedXY 09/19/2025

The SAKK 41/13 trial provides the first prospective randomized evidence that adjuvant aspirin may improve disease-free survival in patients with resected PIK3CA-mutated stage II and III colon cancer, suggesting its potential as a safe, cost-effective adjuvant strategy.

Clinical Updates news Oncology Specialties

Low-Dose Aspirin’s Impact on PI3K-Altered Localized Colorectal Cancer: New Evidence from a Randomized Controlled Trial

By MedXY 09/19/2025

This randomized trial confirms that daily low-dose aspirin significantly reduces colorectal cancer recurrence in patients with PI3K pathway mutations, highlighting a targeted adjunctive therapy option.

Cardiology news Specialties

Clopidogrel Surpasses Aspirin: Comprehensive Meta-Analysis Shows Superior Secondary Prevention in Coronary Artery Disease

By MedXY 09/02/2025

A large meta-analysis in The Lancet demonstrates that clopidogrel reduces MACCE risk by 14% over aspirin in CAD secondary prevention, with comparable safety over 5.5 years.

Oncology Specialties

Evaluating the Adjuvant Role of Low-Dose Aspirin in Cancer-Associated Venous Thromboembolism: Efficacy, Safety, and Clinical Implications

By MedXY 08/21/2025

Low-dose aspirin added to anticoagulation for cancer-associated VTE reduces recurrence and PE-related mortality but increases bleeding risk, without improving overall survival or net clinical benefit over 6 months.

Clinical Updates Neurology Specialties

Mechanical Thrombectomy in Distal Medium MCA Occlusion: Impact of Pre-Stroke Low-Dose Aspirin on Efficacy and Safety

By MedXY 08/17/2025

Pre-stroke low-dose aspirin in distal medium vessel occlusion stroke patients undergoing mechanical thrombectomy is linked to improved 90-day functional outcomes and reduced mortality without increased symptomatic hemorrhage risk.

Cardiology Specialties

Evaluating Aspirin Plus Rivaroxaban versus Rivaroxaban Alone to Prevent Venous Stent Thrombosis in Post-Thrombotic Syndrome: Insights from the ARIVA Trial

By MedXY 08/17/2025

The ARIVA trial found no superior benefit of adding aspirin to rivaroxaban over rivaroxaban alone in preventing venous stent thrombosis within 6 months post-intervention in post-thrombotic syndrome patients, with both regimens showing high patency and safety.